Targeting Cellular Senescence for Age-Related Diseases: Path to Clinical Translation
暂无分享,去创建一个
[1] J. Campisi,et al. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice , 2021, Nature Metabolism.
[2] J. Kirkland,et al. Strategies for late phase preclinical and early clinical trials of senolytics , 2021, Mechanisms of Ageing and Development.
[3] G. Kuchel,et al. Strategies for targeting senescent cells in human disease , 2021, Nature Aging.
[4] J. Kirkland,et al. Impact of Senescent Cell Subtypes on Tissue Dysfunction and Repair: Importance and Research Questions , 2021, Mechanisms of Ageing and Development.
[5] J. Gil,et al. Senescence and the SASP: many therapeutic avenues , 2020, Genes & development.
[6] M. Quante,et al. Senolytics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantation , 2020, Nature Communications.
[7] L. Nicholas. Geriatric dermatology. , 2020, The Journal of the Medical Society of New Jersey.
[8] J. Kirkland,et al. Senolytic drugs: from discovery to translation , 2020, Journal of internal medicine.
[9] Amanda R. Kulick,et al. Senolytic CAR T cells reverse senescence-associated pathologies , 2020, Nature.
[10] J. Elisseeff,et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity , 2020, Nature Communications.
[11] M. Mildner,et al. Organotypic human skin culture models constructed with senescent fibroblasts show hallmarks of skin aging , 2020, npj Aging and Mechanisms of Disease.
[12] J. Kirkland,et al. Discovery, development, and future application of senolytics: theories and predictions , 2020, The FEBS journal.
[13] Shahrukh K Hashmi,et al. Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ EBioMedicine 47 (2019) 446–456 , 2020, EBioMedicine.
[14] H. Nakagami. Cellular senescence and senescence‐associated T cells as a potential therapeutic target , 2019, Geriatrics & gerontology international.
[15] Shahrukh K Hashmi,et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease , 2019, EBioMedicine.
[16] A. Alimonti,et al. Cellular Senescence: Aging, Cancer, and Injury. , 2019, Physiological reviews.
[17] A. Bhushan,et al. Activation of the mTORC1/PGC-1 axis promotes mitochondrial biogenesis and induces cellular senescence in the lung epithelium. , 2019, American journal of physiology. Lung cellular and molecular physiology.
[18] S. Kritchevsky,et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study , 2019, EBioMedicine.
[19] Jun-Ping Liu,et al. Roles of Telomere Biology in Cell Senescence, Replicative and Chronological Ageing , 2019, Cells.
[20] N. Fortunel,et al. Age-related evolutions of the dermis: Clinical signs, fibroblast and extracellular matrix dynamics , 2019, Mechanisms of Ageing and Development.
[21] I. Ovsyannikova,et al. Senescent cell clearance by the immune system: Emerging therapeutic opportunities. , 2018, Seminars in immunology.
[22] J. Kirkland,et al. Aging, Cell Senescence, and Chronic Disease: Emerging Therapeutic Strategies. , 2018, JAMA.
[23] P. Robbins,et al. Fisetin is a senotherapeutic that extends health and lifespan , 2018, EBioMedicine.
[24] D. Torella,et al. Aged‐senescent cells contribute to impaired heart regeneration , 2018, bioRxiv.
[25] F. Mulero,et al. A versatile drug delivery system targeting senescent cells , 2018, EMBO molecular medicine.
[26] M. Demaria,et al. Hallmarks of Cellular Senescence. , 2018, Trends in cell biology.
[27] L. Feng,et al. Senescent cells re‐engineered to express soluble programmed death receptor‐1 for inhibiting programmed death receptor‐1/programmed death ligand‐1 as a vaccination approach against breast cancer , 2018, Cancer science.
[28] D. Allison,et al. Senolytics Improve Physical Function and Increase Lifespan in Old Age , 2018, Nature Medicine.
[29] J. Gil,et al. Mechanisms and functions of cellular senescence. , 2018, The Journal of clinical investigation.
[30] M. Giacca,et al. Identification of HSP90 inhibitors as a novel class of senolytics , 2017, Nature Communications.
[31] L. Niedernhofer,et al. The Clinical Potential of Senolytic Drugs , 2017, Journal of the American Geriatrics Society.
[32] Yossi Ovadya,et al. Quantitative identification of senescent cells in aging and disease , 2017, Aging cell.
[33] J. Kirkland,et al. Cellular Senescence: A Translational Perspective , 2017, EBioMedicine.
[34] Wiggert A. van Cappellen,et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging , 2017, Cell.
[35] P. Robbins,et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463 , 2017, Aging.
[36] Daohong Zhou,et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents , 2016, Aging.
[37] S. Austad,et al. Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.
[38] Cory B. Giles,et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors , 2016, Aging cell.
[39] W. Vainchenker,et al. P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis , 2016, Oncotarget.
[40] J. Kirkland. Translating the Science of Aging into Therapeutic Interventions. , 2016, Cold Spring Harbor perspectives in medicine.
[41] A. Pezeshki,et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan , 2016, Nature.
[42] M. Jensen,et al. Targeting senescent cells enhances adipogenesis and metabolic function in old age , 2015, eLife.
[43] N. Sharpless,et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice , 2015, Nature Medicine.
[44] N. LeBrasseur,et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs , 2015, Aging cell.
[45] Dolores Diaz,et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy , 2015, Science Translational Medicine.
[46] J. Praestgaard,et al. mTOR inhibition improves immune function in the elderly , 2014, Science Translational Medicine.
[47] J. Hoeijmakers,et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. , 2014, Developmental cell.
[48] E. Schadt,et al. Geroscience: Linking Aging to Chronic Disease , 2014, Cell.
[49] J. Kirkland,et al. Cellular senescence and the senescent secretory phenotype in age-related chronic diseases , 2014, Current opinion in clinical nutrition and metabolic care.
[50] Manuel Serrano,et al. The Hallmarks of Aging , 2013, Cell.
[51] J. Campisi,et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. , 2013, The Journal of clinical investigation.
[52] J. Kirkland. Translating advances from the basic biology of aging into clinical application , 2013, Experimental Gerontology.
[53] D. Lewis,et al. Reversing the aging stromal phenotype prevents carcinoma initiation , 2011, Aging.
[54] W. Wilson,et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.
[55] J. Campisi,et al. Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo , 2009, Nature Protocols.
[56] Yves Pommier,et al. γH2AX and cancer , 2008, Nature Reviews Cancer.
[57] Jill P. Mesirov,et al. GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..
[58] A. Terzic,et al. Individualized Medicine and the Imperative of Global Health , 2007, Clinical pharmacology and therapeutics.
[59] D. Cortese,et al. A Vision of Individualized Medicine in the Context of Global Health , 2007, Clinical pharmacology and therapeutics.
[60] Stephanie Studenski,et al. Geriatric Syndromes: Clinical, Research, and Policy Implications of a Core Geriatric Concept , 2007, Journal of the American Geriatrics Society.
[61] N. Sharpless,et al. Ink4a/Arf expression is a biomarker of aging. , 2004, The Journal of clinical investigation.
[62] Contet‐Audonneau,et al. A histological study of human wrinkle structures: comparison between sun‐exposed areas of the face, with or without wrinkles, and sun‐protected areas , 1999, The British journal of dermatology.
[63] J. Campisi. The role of cellular senescence in skin aging. , 1998, The journal of investigative dermatology. Symposium proceedings.
[64] C Roskelley,et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[65] E. Wang,et al. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. , 1995, Cancer research.
[66] L. Hayflick. THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. , 1965, Experimental cell research.
[67] N. LeBrasseur,et al. Cellular Senescence and the Biology of Aging, Disease, and Frailty. , 2015, Nestle Nutrition Institute workshop series.
[68] F W Pirruccello,et al. Plastic and reconstructive surgery. , 1967, IMJ. Illinois medical journal.